Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life

Figure 2

Odds ratios for patients' characteristics potentially associated with KI benefit response after the second treatment cycle. CI = confidence interval, KI = Karnofsky Index. Odds ratios derived from univariate regression analyses, including all eligible patients (N = 521). Reference categories: KI at baseline = < 80%, prior first-line chemotherapy = single agent, time elapsed since prior chemotherapy = immediately, Grade 3/4 toxicities = none. Time elapsed since prior chemotherapy: Immediately = first dose of pemetrexed given ≤ 28 days after the last dose of first-line therapy. Within 3 months = first dose of pemetrexed given > 28 days but ≤ 3 months after the last dose of first-line therapy. Later than 3 months: first dose of pemetrexed given > 3 months after the last dose of first-line therapy

Back to article page
\